These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Use of enterocin S760 for prevention and treatment of experimental Salmonella infection in mice]. Svetoch EA; Borzilov AI; Eruslanov BV; Korobova OV; Teĭmurazov MG; Kombarova TI; Diatlov IA Zh Mikrobiol Epidemiol Immunobiol; 2010; (5):44-8. PubMed ID: 21061577 [TBL] [Abstract][Full Text] [Related]
4. Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice. Brook I; Germana A; Giraldo DE; Camp-Hyde TD; Bolduc DL; Foriska MA; Elliott TB; Thakar JH; Shoemaker MO; Jackson WE; Ledney GD J Antimicrob Chemother; 2005 Dec; 56(6):1074-80. PubMed ID: 16239289 [TBL] [Abstract][Full Text] [Related]
5. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Heine HS; Purcell BK; Bassett J; Miller L; Goldstein BP Antimicrob Agents Chemother; 2010 Mar; 54(3):991-6. PubMed ID: 20047912 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Heine HS; Bassett J; Miller L; Bassett A; Ivins BE; Lehoux D; Arhin FF; Parr TR; Moeck G Antimicrob Agents Chemother; 2008 Sep; 52(9):3350-7. PubMed ID: 18606841 [TBL] [Abstract][Full Text] [Related]
8. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178 [TBL] [Abstract][Full Text] [Related]
10. A Review of the Efficacy of FDA-Approved Couse Z; Cui X; Li Y; Moayeri M; Leppla S; Eichacker PQ Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33450877 [TBL] [Abstract][Full Text] [Related]
11. The designer proline-rich antibacterial peptide A3-APO prevents Bacillus anthracis mortality by deactivating bacterial toxins. Otvos L; Flick-Smith H; Fox M; Ostorhazi E; Dawson RM; Wade JD Protein Pept Lett; 2014 Apr; 21(4):374-81. PubMed ID: 24164262 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Manzulli V; Fasanella A; Parisi A; Serrecchia L; Donatiello A; Rondinone V; Caruso M; Zange S; Tscherne A; Decaro N; Pedarra C; Galante D J Vet Sci; 2019 Jan; 20(1):58-62. PubMed ID: 30541185 [TBL] [Abstract][Full Text] [Related]
13. Raxibacumab for inhalational anthrax: an effective specific therapeutic approach? Antoniu SA Expert Opin Investig Drugs; 2010 Jul; 19(7):909-11. PubMed ID: 20450444 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. Gill SC; Rubino CM; Bassett J; Miller L; Ambrose PG; Bhavnani SM; Beaudry A; Li J; Stone KC; Critchley I; Janjic N; Heine HS Antimicrob Agents Chemother; 2010 May; 54(5):1678-83. PubMed ID: 20145081 [TBL] [Abstract][Full Text] [Related]